Breast cancer circulating biomarkers: advantages, drawbacks, and new insights
Daniele Generali(University of Trieste), Alberto Bottini(University of Genoa), Paola Brambilla(University of Milan), Francesco Lanza(Ospedale "Santa Maria delle Croci" di Ravenna), Chiara Senti(Istituti Ospitalieri di Cremona), Simone Anfossi(The University of Texas MD Anderson Cancer Center), Maria Rosa Cappelletti(University of Trieste), James M. Reuben(The University of Texas MD Anderson Cancer Center), Paolo Pedrazzoli(Policlinico San Matteo Fondazione), Massimo Martino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Laura Zanotti(Istituti Ospitalieri di Cremona), Andrea Ravelli(The University of Texas MD Anderson Cancer Center), Manuela Milani(Humanitas University), Daniele Spada(Policlinico San Matteo Fondazione), Angela Gobbi(Istituti Ospitalieri di Cremona)
Cited by 47
Related Papers
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
|Journal of Clinical Oncology|2001|610
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Liposomal Amphotericin B for the Treatment of Systemic Fungal Infections in Patients with Cancer: A Preliminary Study
|The Journal of Infectious Diseases|1985|408
Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually
|Bone Marrow Transplantation|2016|396